Highest-materiality recent filing
Synopsys appoints Elliott's Jesse Cohn to board under cooperation agreement
Jesse Cohn, Managing Partner at Elliott, appointed to Synopsys board effective June 1, 2026; board expands to 11.
Synopsys Q2 revenue $2.276B beats guidance; raises FY rev to $9.665B midpoint
Q2 revenue $2.276B (above prior guidance), up 42% YoY; non-GAAP EPS $3.35, GAAP EPS $0.09.
Synopsys shareholders approve amended equity plan extending awards to non-employee directors
Shareholders approved Amended and Restated Equity Incentive Plan on Apr 16, 2026; plan now allows non-employee directors to receive awards.
Synopsys enters $250M accelerated share repurchase agreement with Bank of Nova Scotia
Initial delivery of approximately 513,000 shares; final settlement by June 1, 2026.
Synopsys Q1 FY2026 revenue $2.409B, non-GAAP EPS $3.77; board authorizes $2B buyback
Revenue $2.409B (high-end of guidance); GAAP EPS $0.34, non-GAAP EPS $3.77 above guidance.
Synopsys appoints former Deloitte interim CEO Peter Shimer to board; Borgen, Gopal not renominated
Peter A. Shimer appointed to board and audit committee, effective Feb 14, 2026.
Synopsys posts record FY2025 revenue $7.054B; Q4 beats midpoint; FY2026 guidance $9.61B
Record full-year 2025 revenue $7.054B (+15% YoY); Q4 revenue $2.255B exceeded midpoint; Ansys contributed $667.7M.
Synopsys and NVIDIA announce strategic partnership; NVIDIA invests $2B in SNPS stock
NVIDIA purchased 4,821,717 shares of Synopsys common stock at $414.79/share for $2B cash.
Synopsys plans 10% workforce reduction; estimates $300M-$350M in pre-tax charges
Board approved restructuring on Nov 9, 2025; workforce reduction of ~10% of FY2025 year-end headcount.
Synopsys CRO Rick Mahoney departs effective immediately; FY2025 guidance reaffirmed
Rick Mahoney has left the role of Chief Revenue Officer, effective immediately on November 4, 2025; search for successor is advanced.
Synopsys appoints Vijayaraghavan to Board's Governance and Nominating Committee
Mr. Vijayaraghavan was appointed to the Board on July 17, 2025, as previously reported.
Synopsys Q3 FY2025 revenue up 14% to $1.74B; GAAP EPS $1.50 vs $2.73 YoY
Revenue $1.740B (+14% YoY); GAAP net income $242.5M ($1.50 diluted EPS) vs $425.9M ($2.73) YoY.
Synopsys completes acquisition of Ansys; exchange ratio adjusted, board adds two Ansys directors
Each Ansys share converted to ~0.34 Synopsys shares + ~$199.91 cash; ratio adjusted to stay under 19.999% issuance cap.
Synopsys receives all regulatory approvals for Ansys acquisition; closing expected July 17
All necessary regulatory approvals received for the pending acquisition of Ansys.
US Commerce Dept rescinds China export restrictions on Synopsys, effective July 2
BIS rescinded China-related export restrictions previously imposed on May 29, 2025, effective immediately.
Synopsys suspends FY2025 guidance after receiving new BIS China export restrictions
Received BIS letter on May 29, 2025 imposing new export restrictions related to China.
Synopsys Q2 revenue $1.604B, GAAP EPS $2.24, non-GAAP EPS $3.67; reaffirms FY2025 guidance
Revenue $1.604B (+10.2% YoY from $1.455B), exceeding midpoint of guidance.
Stockholders approved an amendment to the 2006 Employee Equity Incentive Plan to increase authorized shares by 1,600,000; vote 120.2M for, 5.7M against.
Issued $10B aggregate principal: $1B 4.550% notes due 2027, $1B 4.650% due 2028, $2B 4.850% due 2030, $1.5B 5.000% due 2032, $2.4B 5.150% due 2035, $2.1B 5.700% due 2055.
Synopsys raises $10B in senior notes offering to fund Ansys acquisition
Issued $10B in senior notes across six tranches: 2027 (4.55%), 2028 (4.65%), 2030 (4.85%), 2032 (5.00%), 2035 (5.15%), and 2055 (5.70%).
Synopsys files Ansys FY2024 audited financials and updated pro forma merger statements
Ansys FY2024 revenue $2.545B, net income $575.7M; FY2023 revenue $2.270B, net income $500.4M.
Synopsys Q1 revenue $1.455B, non-GAAP EPS $3.03; reaffirms FY2025 guidance
Q1 revenue $1.455B, down from $1.511B YoY; exceeded midpoint of guidance.
Synopsys Q4 FY24 revenue $1.636B, up 11% YoY; non-GAAP EPS $3.40 beats guidance
Record quarterly revenue $1.636B, up ~11% YoY; full-year revenue $6.127B, up ~15% YoY.
Synopsys changes fiscal year-end to Oct 31; quarterly periods shift to calendar month-ends
Board approved change from 52/53-week fiscal year ending Sat near Oct 31 to Oct 31 calendar date, effective FY2025.
Synopsys completes sale of Software Integrity unit to Clearlake and Francisco Partners
Sale completed on Sept 30, 2024; buyers are entities controlled by Clearlake Capital and Francisco Partners.
Synopsys Q3 FY2024 revenue record $1.526B, non-GAAP EPS $3.43 beat guidance
Record Q3 revenue $1.526B (+13% YoY); GAAP EPS $2.73; non-GAAP EPS $3.43 (+27% YoY).
Submitted transaction notification to China's State Administration for Market Regulation on July 10, 2024.
Synopsys Q2 revenue $1.455B (+15% YoY), non-GAAP EPS $3.00 (+26%); raises FY2024 targets
GAAP net income $299.1M ($1.92/diluted share); non-GAAP net income $466.9M ($3.00/diluted share), beating guidance.
There are no arrangements or understandings between Mr. Cohn and any other person pursuant to which Mr. Cohn was appointed as a director
Max materiality 1.00 · Median 0.72 · Most common event earnings